While this is a proven and effective strategy in some cases, like the gliptin class of dipeptidyl-peptidase 4 inhibitors for the treatment of type 2 diabetes [4], it can also cause significant on or off-target side effects that can ultimately prohibit the use of the inhibitor in the clinic. Here, DPP4 is linked to type 2 diabetes mellitus.